<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502034</url>
  </required_header>
  <id_info>
    <org_study_id>POLAR 01</org_study_id>
    <nct_id>NCT00502034</nct_id>
  </id_info>
  <brief_title>Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.</brief_title>
  <official_title>Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico Italiano di Ricerca Clinica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Oncologico Italiano di Ricerca Clinica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy (in terms of event-free survival and overall
      survival) of an adjuvant therapy with IFN-alpha plus low-dose of IL2 vs a wait-and-see
      program in patient with radically operated renal cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For pts with non-metastatic RCC, no standard adjuvant treatment exists. Immunotherapy (IT)
      using IFN and/or IL2 is effective in metastatic disease setting. Low and chronically repeated
      doses of IL2 plus IFN induce a persistent stimulation of the immune system with no relevant
      toxicity.

      Surgically treated RCC pts were randomized to the following arms: A) low-dose IT; B) control
      arm. IT consisted of a 4-week cycle of s.c. IL2 (5 days/wk, 1 million UI/sqm bid d 1,2 and 1
      million UI/sqm x 1 d 3,4,5) + IFN (1,8 million UI/sqm d 3,5 of each week). Cycles were
      repeated every 4 months for the first 2 years and every 6 months for the remaining 3 years.
      Each patient received 12 cycles in 5 years. Inclusion criteria were as follows: histological
      diagnosis of RCC, age &lt;75 yrs, radical or partial nephrectomy within the past 3 months, pT1
      (diameter of T &gt; 2,5 cm), T2, T3 a-b-c; pN0-pN3, M0; good cardiac and renal function and no
      autoimmune disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1994</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival: loco-regional, adrenal, kidney and distant-metastases were the events considered for event-free survival.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability, toxicity and safety.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>A-immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunotherapy with interferon-alpha and interleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Wait-and-see</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Alfa-2a</intervention_name>
    <description>Interferon Alfa-2a in combination with Interleukin</description>
    <arm_group_label>A-immunotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Interferon Alfa-2a in combination with Interleukin</description>
    <arm_group_label>A-immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis histologically confirmed of renal cells carcinoma (every histotype);

          -  Age &lt; 75 years

          -  Radical surgical removal of the tumor: total or partial nephrectomy within previous 3
             months

          -  Patient classified as T1 (with diameter &gt; 2,5 cm), T2, T3 a-b-c; In presence of
             involvement of loco-regional lymph-nodes (staging N1, N2, N3, TNM class.), metastases
             should have been completely removed during nephrectomy

          -  Absence of distant metastases;

          -  Written informed consent

        Exclusion Criteria:

          -  Tumor diameter equal or less than 2,5 cm;

          -  Previous chemotherapy or ormonotherapy o immunotherapy;

          -  Renal insufficiency &gt;3 mg/dl);

          -  No symptomatic arrhythmias or autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Passalacqua, Medicine</last_name>
    <role>Study Chair</role>
    <affiliation>Gruppo Oncologico Italiano di Ricerca Clinica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlo Buzio, Medicine</last_name>
    <role>Study Chair</role>
    <affiliation>Parma University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carpi Hospital</name>
      <address>
        <city>Carpi</city>
        <state>Modena</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Ospitalieri di Cremona</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modena University Hospital</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parma University Hospital</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavia University Hospital</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Guglielmo da Saliceto&quot;</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.goirc.it</url>
    <description>Official Web Site of GOIRC</description>
  </link>
  <reference>
    <citation>Passalacqua R, Buti S, Tomasello G, Longarini R, Brighenti M, Dalla Chiesa M. Immunotherapy options in metastatic renal cell cancer: where we are and where we are going. Expert Rev Anticancer Ther. 2006 Oct;6(10):1459-72. Review.</citation>
    <PMID>17069530</PMID>
  </reference>
  <reference>
    <citation>Giacosa R, Santi R, Vaglio A, Pavone L, Ferrozzi F, Passalacqua R, Buzio C. &quot;Late&quot; regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen. Acta Biomed. 2004 Aug;75(2):126-30.</citation>
    <PMID>15481703</PMID>
  </reference>
  <reference>
    <citation>Buzio C, Andrulli S, Santi R, Pavone L, Passalacqua R, Potenzoni D, Ferrozzi F, Giacosa R, Vaglio A. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer. 2001 Nov 1;92(9):2286-96.</citation>
    <PMID>11745283</PMID>
  </reference>
  <reference>
    <citation>Buzio C, De Palma G, Passalacqua R, Potenzoni D, Ferrozzi F, Cattabiani MA, Manenti L, Borghetti A. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer. 1997;76(4):541-4.</citation>
    <PMID>9275034</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2007</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Renal Cell</keyword>
  <keyword>Low-dose Interleukin</keyword>
  <keyword>Adjuvant Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

